Hafnia alvei: Difference between revisions
From IDWiki
Hafnia alvei
Content deleted Content added
No edit summary |
|||
| Line 10: | Line 10: | ||
== Management == |
== Management == |
||
* Reliably susceptible to [[imipenem]], [[ciprofloxacin]], |
* Reliably susceptible to [[imipenem]], cefepime, [[ciprofloxacin]], aminoglycosides, [[cotrimoxazole]][[CiteRef::gunthard1996cl]][[CiteRef::ramos2000ex]][[CiteRef::bhardwaj2025ch]] |
||
** Often susceptible to [[nitrofurantoin]][[CiteRef::CiteRef::lancelevee2007an]] |
|||
* May be susceptible to [[ceftriaxone]] and [[ceftazidime]], but may have inducible resistance[[CiteRef::lancelevee2007an]] |
* May be susceptible to [[ceftriaxone]] and [[ceftazidime]], but may have inducible resistance[[CiteRef::lancelevee2007an]] |
||
* Unreliably susceptible to cephalothin and [[amoxicillin-clavulanic acid]] and [[piperacillin]][[CiteRef::bhardwaj2025ch]][[CiteRef::lancelevee2007an]] |
|||
[[Category:Gram-negative bacilli]] |
[[Category:Gram-negative bacilli]] |
||
Latest revision as of 12:47, 20 June 2025
Background
- Gram-negative bacillus in the genus Hafnia
- Rare cause of disease in humans
Clinical Manifestations
- Can cause bacteremia, gastroenteritis, meningitis, pneumonia, nosocomial wound infections, hepatobiliary infections, psoas abscess, prosthetic valve endocarditis, and endophthalmitis12
Management
- Reliably susceptible to imipenem, cefepime, ciprofloxacin, aminoglycosides, cotrimoxazole123
- Often susceptible to nitrofurantoin4
- May be susceptible to ceftriaxone and ceftazidime, but may have inducible resistance5
- Unreliably susceptible to cephalothin and amoxicillin-clavulanic acid and piperacillin35
References
- a b H. Gunthard, A. Pennekamp. Clinical Significance of Extraintestinal Hafnia alvei Isolates from 61 Patients and Review of the Literature. Clinical Infectious Diseases. 1996;22(6):1040-1045. doi:10.1093/clinids/22.6.1040.
- a b A. Ramos, D. Dámaso. Extraintestinal Infection due to Hafnia alvei. European Journal of Clinical Microbiology & Infectious Diseases. 2000;19(9):708-710. doi:10.1007/s100960000356.
- a b Vaasu Bhardwaj, Matthew Larsen, Minahil Cheema, John N. Greene. Characterization of Hafnia Infections in Cancer Patients. Infectious Diseases in Clinical Practice. 2025;33(3). doi:10.1097/ipc.0000000000001459.
- ^ CiteRef::lancelevee2007an
- a b J. Lancelevee, L. Bret, K. David, P. Di Martino. Antibiotic Resistance and Adherence Properties ofHafnia alveiClinical Isolates: A 19-Month Study in the Hospital of Orléans, France. Journal of Chemotherapy. 2007;19(6):677-681. doi:10.1179/joc.2007.19.6.677.
